PortalPublikationenCellular immune responses and viral diversity in individuals...

Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection

Standard

Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. / Altfeld, Marcus; Rosenberg, E S; Shankarappa, R; Mukherjee, J S; Hecht, F M; Eldridge, R L; Addo, M M; Poon, S H; Phillips, M N; Robbins, G K; Sax, P E; Boswell, S; Kahn, J O; Brander, C; Goulder, P J; Levy, J A; Mullins, J I; Walker, B D.

in: J EXP MED, Jahrgang 193, Nr. 2, 15.01.2001, S. 169-80.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Altfeld, M, Rosenberg, ES, Shankarappa, R, Mukherjee, JS, Hecht, FM, Eldridge, RL, Addo, MM, Poon, SH, Phillips, MN, Robbins, GK, Sax, PE, Boswell, S, Kahn, JO, Brander, C, Goulder, PJ, Levy, JA, Mullins, JI & Walker, BD 2001, 'Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection', J EXP MED, Jg. 193, Nr. 2, S. 169-80. https://doi.org/10.1084/jem.193.2.169

APA

Altfeld, M., Rosenberg, E. S., Shankarappa, R., Mukherjee, J. S., Hecht, F. M., Eldridge, R. L., Addo, M. M., Poon, S. H., Phillips, M. N., Robbins, G. K., Sax, P. E., Boswell, S., Kahn, J. O., Brander, C., Goulder, P. J., Levy, J. A., Mullins, J. I., & Walker, B. D. (2001). Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J EXP MED, 193(2), 169-80. https://doi.org/10.1084/jem.193.2.169

Vancouver

Altfeld M, Rosenberg ES, Shankarappa R, Mukherjee JS, Hecht FM, Eldridge RL et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J EXP MED. 2001 Jan 15;193(2):169-80. https://doi.org/10.1084/jem.193.2.169

Bibtex

@article{918772afb6c04da1b0690b5f71651cb6,
title = "Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection",
abstract = "Immune responses induced during the early stages of chronic viral infections are thought to influence disease outcome. Using HIV as a model, we examined virus-specific cytotoxic T lymphocytes (CTLs), T helper cells, and viral genetic diversity in relation to duration of infection and subsequent response to antiviral therapy. Individuals with acute HIV-1 infection treated before seroconversion had weaker CTL responses directed at fewer epitopes than persons who were treated after seroconversion. However, treatment-induced control of viremia was associated with the development of strong T helper cell responses in both groups. After 1 yr of antiviral treatment initiated in acute or early infection, all epitope-specific CTL responses persisted despite undetectable viral loads. The breadth and magnitude of CTL responses remained significantly less in treated acute infection than in treated chronic infection, but viral diversity was also significantly less with immediate therapy. We conclude that early treatment of acute HIV infection leads to a more narrowly directed CTL response, stronger T helper cell responses, and a less diverse virus population. Given the need for T helper cells to maintain effective CTL responses and the ability of virus diversification to accommodate immune escape, we hypothesize that early therapy of primary infection may be beneficial despite induction of less robust CTL responses. These data also provide rationale for therapeutic immunization aimed at broadening CTL responses in treated primary HIV infection.",
keywords = "Acute Disease, Amino Acid Sequence, Antiretroviral Therapy, Highly Active, Base Sequence, Cohort Studies, DNA Primers/genetics, Epitopes/genetics, Female, Genetic Variation, HIV Infections/drug therapy, HIV Seropositivity/immunology, HIV-1/genetics, Humans, Immunity, Cellular, Longitudinal Studies, Male, Molecular Sequence Data, RNA, Viral/blood, T-Lymphocytes, Cytotoxic/immunology, T-Lymphocytes, Helper-Inducer/immunology, Time Factors",
author = "Marcus Altfeld and Rosenberg, {E S} and R Shankarappa and Mukherjee, {J S} and Hecht, {F M} and Eldridge, {R L} and Addo, {M M} and Poon, {S H} and Phillips, {M N} and Robbins, {G K} and Sax, {P E} and S Boswell and Kahn, {J O} and C Brander and Goulder, {P J} and Levy, {J A} and Mullins, {J I} and Walker, {B D}",
year = "2001",
month = jan,
day = "15",
doi = "10.1084/jem.193.2.169",
language = "English",
volume = "193",
pages = "169--80",
journal = "J EXP MED",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "2",

}

RIS

TY - JOUR

T1 - Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection

AU - Altfeld, Marcus

AU - Rosenberg, E S

AU - Shankarappa, R

AU - Mukherjee, J S

AU - Hecht, F M

AU - Eldridge, R L

AU - Addo, M M

AU - Poon, S H

AU - Phillips, M N

AU - Robbins, G K

AU - Sax, P E

AU - Boswell, S

AU - Kahn, J O

AU - Brander, C

AU - Goulder, P J

AU - Levy, J A

AU - Mullins, J I

AU - Walker, B D

PY - 2001/1/15

Y1 - 2001/1/15

N2 - Immune responses induced during the early stages of chronic viral infections are thought to influence disease outcome. Using HIV as a model, we examined virus-specific cytotoxic T lymphocytes (CTLs), T helper cells, and viral genetic diversity in relation to duration of infection and subsequent response to antiviral therapy. Individuals with acute HIV-1 infection treated before seroconversion had weaker CTL responses directed at fewer epitopes than persons who were treated after seroconversion. However, treatment-induced control of viremia was associated with the development of strong T helper cell responses in both groups. After 1 yr of antiviral treatment initiated in acute or early infection, all epitope-specific CTL responses persisted despite undetectable viral loads. The breadth and magnitude of CTL responses remained significantly less in treated acute infection than in treated chronic infection, but viral diversity was also significantly less with immediate therapy. We conclude that early treatment of acute HIV infection leads to a more narrowly directed CTL response, stronger T helper cell responses, and a less diverse virus population. Given the need for T helper cells to maintain effective CTL responses and the ability of virus diversification to accommodate immune escape, we hypothesize that early therapy of primary infection may be beneficial despite induction of less robust CTL responses. These data also provide rationale for therapeutic immunization aimed at broadening CTL responses in treated primary HIV infection.

AB - Immune responses induced during the early stages of chronic viral infections are thought to influence disease outcome. Using HIV as a model, we examined virus-specific cytotoxic T lymphocytes (CTLs), T helper cells, and viral genetic diversity in relation to duration of infection and subsequent response to antiviral therapy. Individuals with acute HIV-1 infection treated before seroconversion had weaker CTL responses directed at fewer epitopes than persons who were treated after seroconversion. However, treatment-induced control of viremia was associated with the development of strong T helper cell responses in both groups. After 1 yr of antiviral treatment initiated in acute or early infection, all epitope-specific CTL responses persisted despite undetectable viral loads. The breadth and magnitude of CTL responses remained significantly less in treated acute infection than in treated chronic infection, but viral diversity was also significantly less with immediate therapy. We conclude that early treatment of acute HIV infection leads to a more narrowly directed CTL response, stronger T helper cell responses, and a less diverse virus population. Given the need for T helper cells to maintain effective CTL responses and the ability of virus diversification to accommodate immune escape, we hypothesize that early therapy of primary infection may be beneficial despite induction of less robust CTL responses. These data also provide rationale for therapeutic immunization aimed at broadening CTL responses in treated primary HIV infection.

KW - Acute Disease

KW - Amino Acid Sequence

KW - Antiretroviral Therapy, Highly Active

KW - Base Sequence

KW - Cohort Studies

KW - DNA Primers/genetics

KW - Epitopes/genetics

KW - Female

KW - Genetic Variation

KW - HIV Infections/drug therapy

KW - HIV Seropositivity/immunology

KW - HIV-1/genetics

KW - Humans

KW - Immunity, Cellular

KW - Longitudinal Studies

KW - Male

KW - Molecular Sequence Data

KW - RNA, Viral/blood

KW - T-Lymphocytes, Cytotoxic/immunology

KW - T-Lymphocytes, Helper-Inducer/immunology

KW - Time Factors

U2 - 10.1084/jem.193.2.169

DO - 10.1084/jem.193.2.169

M3 - SCORING: Journal article

C2 - 11148221

VL - 193

SP - 169

EP - 180

JO - J EXP MED

JF - J EXP MED

SN - 0022-1007

IS - 2

ER -